An observational study in Plaque Psoriasis, sponsored by Power Life Sciences Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-29.
Sponsored by Power Life Sciences Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 766 studies in Psoriasis with a site in United States — 57 open to participants now, 88 under way, 19 of them phase 3. Psoriasis · United States.
Among the 766 studies in Psoriasis with a site in United States, this one is the 33rd largest by planned enrollment of the 90 observational ones that give a count, is one of 25 that started in 2025, is one of 90 observational ones, reaches primary completion later than 23 of the 87 other live ones, and was the 714th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →57 of the 766 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
766 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 99 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 408 observational studies indexed under Psoriasis.
Median enrollment 77 across the 675 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 378 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
526 of 766 have an industry lead sponsor. The 10 most frequent:
Power Life Sciences Inc. is the lead sponsor of 111 studies on the registry; 109 are open to participants now.
Power Life Sciences Inc. has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
24 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 766 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.
The data collected from this study will help improve future outcomes for all plaque psoriasis as well as those in under-represented demographic groups.
Patients with plaque psoriasis who are actively considering enrolling in a clinical trial for said condition, but have not yet completed enrollment and randomization phases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rate of patients who decide to enroll in a plaque psoriasis clinical research.
Time frame: 3 months
Number of plaque psoriasis study participants who remain in clinical study until completion.
Time frame: 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Start is estimated for Apr 2025; primary completion for Apr 2026, 12 months later.
Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 12 months is below that.
Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.